Upstream Bio(UPB)
WALTHAM, MABiotechnology
Focus: Upstream Bio is a public biotech company founded in 2022 focused on therapies for allergic and inflammatory conditions, with a current headcount of 51-200 employees and public market listing. The company is in early clinical stages with no commercial revenue to date.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0
About Upstream Bio
AI assessmentNot HiringNo open roles listed right now. Follow Upstream Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$2M
FY2025
Pipeline & Clinical Trials
UPB-101
HealthyClinical Trials (1)
NCT05653479Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults
Phase 1Help build intelligence for Upstream Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.